

# NANOBIOTIX

## EXPANDING LIFE

### Nanobiotix Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion

June 1, 2021

**Paris, France; Cambridge, Massachusetts (USA); June 1, 2021** – [NANOBIOTIX](#) (Euronext : NANO — NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Bart Van Rhijn, MBA, as chief financial officer and member of the Company’s executive board. Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for potential first-in-class radioenhancer NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeds Philippe Mauberna, who will step down from his roles as chief financial officer and executive board member after 8 years of service to the Company. Mr. Mauberna will assume a temporary role to support the organization during transition.

*“Joining Nanobiotix as its CFO is a true honor,”* said Mr. Van Rhijn. *“I look forward to collaborating with the executive team and the organization at-large to help unlock and capture value with potentially practice-changing technology platforms. The opportunity to make a meaningful contribution to the lives of so many patients, caregivers and healthcare providers is humbling and carries great responsibility.”*

Mr. Van Rhijn brings extensive experience in consultancy, technology, and life sciences industries and joins Nanobiotix after nearly 3 years as chief financial officer at Servier Pharmaceuticals, LLC (Servier US). Prior to Servier US, he held leadership roles in prominent organizations in Europe and North America, including PricewaterhouseCoopers, Philips and Galderma in Head of Tax, Senior Director of Mergers and Acquisitions, and Head of Finance positions. Mr. Van Rhijn’s track record reflects a relentless commitment to streamlining business operations, driving growth, and unlocking value. His varied experiences include the successful reorganization of a healthcare technology-enabled services business, coordination of strategic financing transactions, and the efficient scaling of commercial businesses. Mr. Van Rhijn has a strong commitment to organizational health and empowers his teams to embrace innovation, challenge the status quo, and drive optimal results while putting patients and customers first.

Mr. Van Rhijn received master’s degrees in Civil Law and Tax Law at Leiden University, The Netherlands, obtained his MBA with honors from Babson’s Olin School of Management, and his Certified Management Accountant (CMA) certification from the Institute of Management Accounts. In addition, Mr. Van Rhijn serves on the Advisory Board of a Boston-based healthcare start-up and is a venture partner at an emerging technology fund.

*“As Nanobiotix advances toward potential global commercialization it is critical that we continue to globalize our executive management and diversify our leadership expertise,”* said Nanobiotix co-founder and chief executive officer Laurent Levy. *“Bart Van Rhijn brings critical competencies in commercialization at-scale that we believe will enable us to realize the potential benefits of our novel technologies and reach patients around the world. I know I speak for everyone at Nanobiotix in offering heartfelt thanks to Philippe Mauberna. His tireless effort on behalf of patients, their families, Nanobiotix team members, and shareholders have been instrumental in the growth of our company over the past 8 years. We wish Philippe the best in his future pursuits.”*

Philippe Mauberna joined Nanobiotix as chief financial officer in May 2013 and was appointed to the executive board in August 2013. In his time with the company, Nanobiotix became one of only seven French biotech companies dual-listed on Euronext: Paris and Nasdaq; launched its first pivotal phase III clinical registration study for NBTXR3; and attained a European market approval for NBTXR3 (Hensify®) in soft tissue sarcoma. Mr. Mauberna’s leadership also helped the company more than double in size over the course of his tenure and enabled the creation of the Company’s subsidiaries in Europe and in the United States.

#### **About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Germany and Switzerland.

Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company’s resources are primarily devoted to the development of its lead product candidate— NBTXR3 —which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220104005866/en/): <https://www.businesswire.com/news/home/20220104005866/en/>

*Nanobiotix*

**Communications Department**

*Brandon Owens*  
*VP, Communications*  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

**Investor Relations Department**  
*Kate McNeil*  
*SVP, Investor Relations*  
+1 (609) 678-7388  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

*Media Relations*

**France – Ulysse Communication**  
*Pierre-Louis Germain*  
+ 33 (0) 6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

**US – Porter Novelli**  
*Dan Childs*  
+1 (781) 888-5106  
[Dan.childs@porternovelli.com](mailto:Dan.childs@porternovelli.com)

Source: Nanobiotix